Healthcare ETFs Gain Traction as Investors Seek Stability Amid Market Shifts
The healthcare sector has shifted in its market influence, now ranking as the sixth-largest segment in the S&P 500 Index. Once a leading area, it remains a key focus for investors, especially during periods of rising volatility and weaker tech performance. One popular way to gain exposure is through the Health Care Select Sector SPDR Fund (XLV), an ETF designed to track all healthcare stocks within the index. XLV holds every healthcare company listed in the S&P 500, with each stock weighted by its market capitalisation. Currently, the fund trades at under 18 times trailing earnings, a valuation some analysts view as a compelling entry point. However, the sector itself is far from uniform—it includes high-growth but volatile areas like medical devices, which face pressure from rising interest rates, as well as stable pharmaceutical giants with strong patent protections and steady drug revenues.
The ETF is often seen as a defensive play when markets turn unstable and tech stocks lose momentum. Yet its performance depends on very different sub-sectors. Pharmaceutical firms benefit from global demand and recurring drug sales, while healthcare providers, such as insurers, are heavily influenced by government policies, reimbursement rates, and shifting benefit trends. To help investors navigate these risks, Rob Isbitts, founder of ETFYourself.com, developed the ROAR Score—a tool aimed at managing risk and building customised portfolios. His research focuses on ETFs, offering analysis to those looking to refine their investment strategies.
XLV provides broad access to the healthcare sector, but its varied components mean investors must consider differing risk levels. The fund’s current valuation and defensive reputation may appeal to those seeking stability. Meanwhile, tools like the ROAR Score offer additional ways to assess and balance exposure across the sector’s diverse segments.
